Treatment implications of the schizophrenia prodrome

Current Topics in Behavioral Neurosciences

Volumn 4, Issue , 2010, Pages 97-121

  Kaur, Tejal ^a   Cadenhead, Kristin S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; ICOSAPENTAENOIC ACID; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ARTICLE; COGNITIVE THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MEDICAL ETHICS; NEUROPROTECTION; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SCHIZOPHRENIA PRODROME; SIDE EFFECT; STAGING; WEIGHT GAIN; COGNITIVE DEFECT; PREDICTIVE VALUE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REVIEW;

COGNITION DISORDERS; DISEASE PROGRESSION; GUIDELINES AS TOPIC; HUMANS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79952268095     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2010_56     Document Type: Article

References (103)

1. Addington J, Leriger E, Addington D (2003) Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry 48:204-207
2. Addington J, Van Mastrigt S, Addington D (2004) Duration of untreated psychosis: impact on 2-year outcome. Psychol Med 34:277-284
3. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinssen R (2007) North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull 33:665-672
4. Angelucci F, Mathe AA, Aloe L (2000) Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 60:783-794
5. Arnold S, Beyer C (2009) Neuroprotection by estrogen in the brain: the mitochondrial compartment as presumed therapeutic target. J Neurochem 110:1-11
6. Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110-117
7. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM (2003) Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71:127-131
8. Ballon JS, Kaur T, Marks II, Cadenhead KS (2007) Social functioning in young people at risk for schizophrenia. Psychiatry Res 151:29-35
9. Berger GE, Wood S, McGorry PD (2003) Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol Bull 37:79-101
10. Berger GE, Proffitt TM, McConchie M, Yuen H, Wood SJ, Amminger GP, Brewer W, McGorry PD (2007) Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebocontrolled trial. J Clin Psychiatry 68:1867-1875
11. Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, Lieberman JA, Kane JM (2006) Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol 28:270-282
12. Brewer WJ, Wood SJ, McGorry PD, Francey SM, Phillips LJ, Yung AR, Anderson V, Copolov DL, Singh B, Velakoulis D, Pantelis C (2003) Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am J Psychiatry 160:1790-1794
13. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD (2005) Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 162:71-78
14. Byrd CA, Brunjes PC (2001) Neurogenesis in the olfactory bulb of adult zebrafish. Neuroscience 105:793-801
15. Cadenhead K (2005) The stability of prepulse inhibition of the startle response in individuals atrisk for schizophrenia and in the early phases of illness. Schizophr Bull 31:450
16. Cadenhead K, Light GA, Geyer MA, Braff DL (2000) Sensory gating deficits assessed by the P50 event-related-potential in subjects with schizotypal personality disorder. Am J Psychiatry 157:55-59
17. Cannon TD, van Erp TG, Bearden CE, Loewy R, Thompson P, Toga AW, Huttunen MO, Keshavan MS, Seidman LJ, Tsuang MT (2003) Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull 29:653-669
18. Cannon R, Lubar J, Congedo M, Thornton K, Towler K, Hutchens T (2007) The effects of neurofeedback training in the cognitive division of the anterior cingulate gyrus. Int J Neurosci 117:337-357
19. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008) Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65:28-37
20. Caspi A, Reichenberg A, Weiser M, Rabinowitz J, Kaplan Z, Knobler H, Davidson-Sagi N, Davidson M (2003) Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 65:87-94
21. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005) Moderation of the effect of adolescentonset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117-1127
22. Catts VS, Catts SV (2000) Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res 41:405-415
23. Corcoran C, Malaspina D, Hercher L (2005) Prodromal interventions for schizophrenia vulnerability: the risks of being at "risk". Schizophr Res 73:173-184
24. Cornblatt BA, Lencz T, Kane JM (2001) Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 51:31-38
25. Cornblatt B, Lencz T, Obuchowski M (2002) The schizophrenia prodrome: treatment and highrisk perspectives. Schizophr Res 54:177-186
26. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, Cannon TD (2007a) Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull 33(3):688-702
27. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU (2007b) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 68:546-557
28. Correll CU, Malhotra AK (2004) Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 174:477-489
29. Cosway R, Byrne M, Clafferty R, Hodges A, Grant E, Abukmeil SS, Lawrie SM, Miller P, Johnstone EC (2000) Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol Med 30:1111-1121
30. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M (1999) Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 156:1328-1335
31. Eastvold AD, Cadenhead K (2003) Neurocognitive markers in prodromal schizophrenia. Schizophr Res 60:133
32. Eastvold AD, Heaton RK, Cadenhead KS (2007) Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr Res 93:266-277
33. Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M (2001) Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 10:109-115
34. Feinberg I (1982) Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 17:319-334
35. Grant C, Addington J, Addington D, Konnert C (2001) Social functioning in first-and multiepisode schizophrenia. Can J Psychiatry 46:746-749
36. Hafner H, an der Heiden W (1999) The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4):14-26
37. Häfner H, Riecher-Rössler A, Maurer K, Fätkenheuer B, Löffler W (1992) First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci 242:109-118
38. Haroun N, Dunn L, Haroun A, Cadenhead KS (2006) Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull 32:166-178
39. Harrigan SM, McGorry PD, Krstev H (2003) Does treatment delay in first-episode psychosis really matter? Psychol Med 33:97-110
40. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G (1994) One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 151:1409-1416
41. Huber G, Gross G (1989) The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med 80:646-652
42. Jacobs BL, Praag H, Gage FH (2000) Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 5:262-269
43. Jahshan C, Heaton RK, Golshan S, Cadenhead KS (2010) Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology 24:109-120
44. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA (2000) Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 48:641-650
45. Johannessen JO, Larsen TK, Joa I, Melle I, Friis S, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan TH (2005) Pathways to care for first-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS study. Br J Psychiatry 48: s24-s28
46. Karlsgodt KH, Niendam TA, Bearden CE, Cannon TD (2009) White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosis. Biol Psychiatry 66:562-569
47. Keith SJ, Matthews SM (1991) The diagnosis of schizophrenia: a review of onset and duration issues. Schizophr Bull 17:51-67
48. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158-164
49. Kornack DR, Rakic P (1999) Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Proc Natl Acad Sci USA 96:5768-5773
50. Lappin JM, Morgan K, Morgan C, Hutchison G, Chitnis X, Suckling J, Fearon P, McGuire PK, Jones PB, Leff J, Murray RM, Dazzan P (2006) Gray matter abnormalities associated with duration of untreated psychosis. Schizophr Res 83:145-153
51. Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO (2000) Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 45:1-9
52. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T (2006) Early detection of first-episode psychosis: the effect on 1-year outcome. Schizophr Bull 32:758-764
53. Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46:729-739
54. Linszen D, Dingemans P, Lenior M (2001) Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res 51:55-61
55. Maier W, Mossner R, Quednow BB, Wagner M, Hurlemann R (2008) From genes to psychoses and back: the role of the 5HT2alpha-receptor and prepulse inhibition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 258(Suppl 5):40-43
56. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104-9110
57. Malla AK, Norman RM, Manchanda R, Ahmed MR, Scholten D, Harricharan R, Cortese L, Takhar J (2002) One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res 54:231-242
58. Marshall M, Rathbone J (2006) Early intervention for psychosis. Cochrane Database Syst Rev CD004718
59. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 62:975-983
60. McGlashan TH (2001) Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res 51:47-54
61. McGlashan TH, Vaglum P, Friis S, J. Johannessen O, Simonsen E, Larsen TK, Melle I, Haahr U, Opjordsmoen S, Zipursky R, Perkins D, Addington J, Miller T, Woods S, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, M. Tohen M, Breier A (2005) Early detection and intervention in first episode psychosis: empirical update of the TIPS and PRIME projects. Schizophr Bull 31:496
62. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790-799
63. McGlashan TH, Addington J, Cannon T, Heinimaa M, McGorry P, O'Brien M, Penn D, Perkins D, Salokangas RK, Walsh B, Woods SW, Yung A (2007) Recruitment and treatment practices for help-seeking "prodromal" patients. Schizophr Bull 33:715-726
64. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921-928
65. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ (2006) Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust NZ J Psychiatry 40:616-622
66. McGorry PD, Killackey E, Yung AR (2007) Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 187:S8-S10
67. McNamara RK, Ostrander M, Abplanalp W, Richtand NM, Benoit SC, Clegg DJ (2006) Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot Essent Fatty Acids 75:237-257
68. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, Simonsen E, Rund BR, Vaglum P, McGlashan T (2004) Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry 61:143-150
69. Melle I, Haahr U, Friis S, Hustoft K, Johannessen JO, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T (2005) Reducing the duration of untreated first-episode psychosis-effects on baseline social functioning and quality of life. Acta Psychiatr Scand 112:469-473
70. Meng H, Schimmelmann BG, Koch E, Bailey B, Parzer P, Günter M, Mohler B, Kunz N, Schulte-Markwort M, Felder W, Zollinger R, Bürgin D, Resch F (2009) Basic symptoms in the general population and in psychotic and non-psychotic psychiatric adolescents. Schizophr Res 111:32-38
71. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, Woods SW (2002) Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 159:863-865
72. Miller TJ, McGlashan TH, Rosen JL, Cannon TD, Ventura J, Cadenhead K, McFarlane W, Perkins DO, Pearlso GD, Woods SW (2004) Prodromal assessment using the SIPS and SOPS. Schizophr Res 70:74
73. Monteleone P, Fabrazzo M, Tortorella A, Maj M (1997) Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71:11-17
74. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 185:291-297
75. Murray CJ, Lopez AD (1996) Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274:740-743
76. Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O'Brien M, Nuechterlein KH, Green MF, Cannon TD (2006) Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res 84:100-111
77. Niendam TA, Bearden CE, Zinberg J, Johnson JK, O'Brien M, Cannon TD (2007) The course of neurocognition and social functioning in individuals at ultra high risk for psychosis. Schizophr Bull 33:772-781
78. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer W, Soulsby B, Desmond P, McGuire PK (2003) Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361:281-288
79. Perkins DO, Gu H, Boteva K, Lieberman JA (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162:1785-1804
80. Petersen L, Nordentoft M, Jeppesen P, Ohlenschaeger J, Thorup A, Christensen TØ, Krarup G, Dahlstrøm J, Haastrup B, Jørgensen P (2005) Improving 1-year outcome in first-episode psychosis: OPUS trial. Br J Psychiatry Suppl 48:s98-s103
81. Power PJ, Bell RJ, Mills R, Herrman-Doig T, Davern M, Henry L, Yuen HP, Khademy-Deljo A, McGorry PD (2003) Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust NZ J Psychiatry 37:414-420
82. Richtand NM, McNamara RK (2008) Serotonin and dopamine interactions in psychosis prevention. Prog Brain Res 172:141-153
83. Ruhrmann S, Schultze-Lutter F, Klosterkotter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl 3):S162-S167
84. Ruhrmann S, Bechdolf A, Kühn KU, Wagner M, Schultze-Lutter F, Janssen B, Maurer K, Häfner H, Gaebel W, Möller HJ, Maier W, Klosterkötter J, LIPS study group (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51:s88-s95
85. Salokangas RK, McGlashan TH (2008) Early detection and intervention of psychosis. A review. Nord J Psychiatry 62:92-105
86. Schaffner KF, McGorry PD (2001) Preventing severe mental illnesses-new prospects and ethical challenges. Schizophr Res 51:3-15
87. Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkötter J (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 36:182-191
88. Steindler DA, Pincus DW (2002) Stem cells and neuropoiesis in the adult human brain. Lancet 359:1047-1054
89. Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ, van Erp TG, Thompson PM, Toga AW, Cannon TD, Pantelis C (2009) Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res 108:85-92
90. Takahashi T, Suzuki M, Tanino R, Zhou SY, Hagino H, Niu L, Kawasaki Y, Seto H, Kurachi M (2007) Volume reduction of the left planum temporale gray matter associated with long duration of untreated psychosis in schizophrenia: a preliminary report. Psychiatry Res 154:209-219
91. Tenn CC, Fletcher PJ, Kapur S (2005) A putative animal model of the "prodromal" state of schizophrenia. Biol Psychiatry 57:586-593
92. Umbricht D, Krljes S (2005) Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76:1-23
93. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17:2785-2795
94. Valmaggia LR, McCrone P, Knapp M, Woolley JB, Broome MR, Tabraham P, Johns LC, Prescott C, Bramon E, Lappin J, Power P, McGuire PK (2009)Economic impact of early intervention in people at high risk of psychosis. Psychol Med 39:1617-1626
95. Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR, Desmond P, Pantelis C (2003) Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull 29:831-843
96. Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:s96-s101
97. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66:1122-1129
98. Yung AR, McGorry PD (1996) The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 22:353-370
99. Yung A, Phillips L, McGorry P, Ward J, Donovan K, Thompson K (2002) Comprehensive Assessment of At Risk Mental States (CAARMS). The PACE Clinic, University of Melbourne, Department of Psychiatry, Melbourne, Australia, In
100. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD (2003) Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 60:21-32
101. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD (2006) Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 84:57-66
102. Yung AR, Yuen HP, Berger G, Francey S, Hung TC, Nelson B, Phillips L, McGorry P (2007) Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 33:673-681
103. Zhang M, Wang M, Li J, Phillips MR (1994) Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients: an 18-month study in Suzhou, Jiangsu. Br J Psychiatry Suppl 24:96-102